Brown, Emily

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 581

International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework

James, C. A., Jongbloed, J. D. H., Hershberger, R. E., Morales, A., Judge, D. P., Syrris, P., Pilichou, K., Domingo, A. M., Murray, B., Cadrin-Tourigny, J., et al. (2021) · Circulation: Genomic and Precision Medicine

Cardiovascular Effects of ExerciseCardiomyopathy and Myosin Studies

Cited by 238

Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association

Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A. (2020) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 148

Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)

Pallazola, V. A., Sathiyakumar, V., Park, J., Vakil, R. M., Toth, P., Lazo-Elizondo, M., Brown, E., Quispe, R., Guallar, E., Banach, M., et al. (2020) · Archives of Medical Science

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 38

Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes

Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides‐Brears, H., Wilding, J. P. H., & Cuthbertson, D. J. (2020) · Diabetic Medicine

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 21